Lau et al 1 recently reported that coadministration of CYP3A4metabolized statins (atorvastatin, simvastatin, and lovastatin) but not pravastatin (fluvastatin and rosuvastatin) inhibited the "antiplatelet activity of clopidogrel in a dose-dependent manner," using an in vitro point-of-care MICROS cell counter (ABX Diagnostics) and the Plateletworks test platform (Helena Laboratories).
Response
We reported that atorvastatin, but not pravastatin, inhibited the "antiplatelet activity of clopidogrel in a dose-dependent manner." 1 We offered no data on simvastatin, lovastatin, fluvastatin, or rosuvastatin, nor did we offer any data on how the atorvastatin-clopidogrel drug-drug interaction might influence clinical outcomes. These subjects require additional evaluation.
We agree with Dr Shechter that testing platelet adhesion and activation would offer a more complete evaluation of platelet function. However, the main observation of our paper was that clopidogrel, a prodrug, is metabolically activated by the cytochrome P450 (CYP) 3A4 and that atorvastatin inhibits this activation. It is the low concentration of the active clopidogrel metabolite that results in an attenuated response to clopidogrel when coadministered with atorvastatin, not a direct competition between the drugs for the adenosine diphosphate (ADP) platelet receptor. Additional data on the pharmacology of this observation have been obtained with in vitro studies using microsomes containing human cytochromes P450. 2 We and others are performing additional platelet aggregation and flow cytometry studies on the interaction of clopidogrel with other CYP 3A4 substrates. Others are developing new thienopyridines with higher bioavailability and better binding characteristics to CYP3A4 and to the P2Y 12 ADP platelet receptor.
